Federal Register / Vol. 87, No. 7 / Tuesday, January 11, 2022 / Notices 1435 

Controlled substance Drug code Schedule 

Amphetamine ... 1100 II 

Lisdexamphetamine.1205 II 

Methylphenidate 1724 II 

Phenylacetone .. 8501 II 

Tapentadol ........ 9780 II 

The company plans to bulk 

manufacture the above-listed controlled 

substances in bulk for distribution to its 

customers. No other activities for these 

drug codes are authorized for this 

registration. 

Brian S. Besser, 

Acting Assistant Administrator. 

[FR Doc. 2022–00325 Filed 1–10–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–942] 

Bulk Manufacturer of Controlled 

Substances Application: Johnson 

Matthey, Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Johnson Matthey, Inc., has 

applied to be registered as a bulk 

manufacturer of basic class(es) of 

controlled substance(s). Refer to 

Supplemental Information listed below 

for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before March 14, 2022. Such persons 

may also file a written request for a 

hearing on the application on or before 

March 14, 2022. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on November 2, 2021, 

Johnson Matthey, Inc., 2003 Nolte Drive 

West Deptford, New Jersey 08066–1742, 

applied to be registered as a bulk 

manufacturer of the following basic 

class(es) of controlled substance(s): 

Controlled Substance Drug 

Code Schedule 

Gamma Hydroxybutyric Acid .. 2010 I 

Marihuana ............................... 7360 I 

Tetrahydrocannabinols ........... 7370 I 

Noroxymorphone .................... 9145 I 

Difenoxin ................................. 9168 I 

Amphetamine .......................... 1100 II 

Methamphetamine .................. 1105 II 

Lisdexamfetamine ................... 1205 II 

Methylphenidate ...................... 1724 II 

Nabilone .................................. 7379 II 

4-Anilino-N-Phenethyl-4-Piperidine (ANPP).8333 II 

Norfentanyl .............................. 8366 II 

Cocaine ................................... 9041 II 

Codeine ................................... 9050 II 

Dihydrocodeine ....................... 9120 II 

Oxycodone .............................. 9143 II 

Hydromorphone ...................... 9150 II 

Diphenoxylate ......................... 9170 II 

Ecgonine ................................. 9180 II 

Hydrocodone ........................... 9193 II 

Levorphanol ............................ 9220 II 

Meperidine .............................. 9230 II 

Methadone .............................. 9250 II 

Methadone intermediate ......... 9254 II 

Morphine ................................. 9300 II 

Thebaine ................................. 9333 II 

Opium tincture ........................ 9630 II 

Oxymorphone ......................... 9652 II 

Noroxymorphone .................... 9668 II 

Alfentanil ................................. 9737 II 

Remifentanil ............................ 9739 II 

Sufentanil ................................ 9740 II 

Tapentadol .............................. 9780 II 

Fentanyl .................................. 9801 II 

The company plans to bulk 

manufacture the listed controlled 

substances for the internal use 

intermediates or for sale to its 

customers. In reference to drug codes 

7360 (Marihuana), and 7370 

(Tetrahydrocannabinols), the company 

plans to bulk manufacture these drugs 

as synthetic. The company plans to bulk 

manufacture for either internal usage as 

intermediates or to sale to customers as 

Active Pharmaceutical Ingredients 

(API). No other activities for these drug 

codes are authorized for this 

registration. 

Brian S. Besser, 

Acting Assistant Administrator. 

[FR Doc. 2022–00326 Filed 1–10–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–944] 

Importer of Controlled Substances 

Application: Nexus Pharmaceuticals, 

Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Nexus Pharmaceuticals, Inc. 

has applied to be registered as an 

importer of basic class(es) of controlled 

substance(s). Refer to Supplemental 

Information listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before February 10, 2022. Such 

persons may also file a written request 

for a hearing on the application on or 

before February 10, 2022. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing must 

be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for a 

hearing should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/OALJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DPW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on October 25, 2021, 

Nexus Pharmaceuticals, Inc., 10300 

128th Avenue, Pleasant Prairie, 

Wisconsin 53158–7338, applied to be 

registered as an importer of the 

following basic class(es) of controlled 

substance(s): 

Controlled 

substance Drug code Schedule 

Remifentanil ...... 9739 I 

The company plans to import the 

listed controlled substance for research 

and analytical testing purposes. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. No other activity for 

this drug code is authorized for this 

registration. 

Brian S. Besser, 

Acting Assistant Administrator. 

[FR Doc. 2022–00329 Filed 1–10–22; 8:45 am] 

BILLING CODE P 


khammond on DSKJM1Z7X2PROD with NOTICES